Squamous Cell Carcinoma of the Oral CavitySquamous Cell Carcinoma of the OropharynxSquamous Cell Carcinoma of the HypopharynxSquamous Cell Carcinoma of the Larynx
Investigational drug(s) / intervention(s)
data collection
data collection: Demography, Social history, Riskfactors, Relevant medical history, Oncological family history, Disease \& treatment history, Molecular Pathology and Results, Treatment data, Response data, progession free survial, overall survival.
Study summary
Prospective, open, non-interventional, multi-center clinical registry study with the aim to establish a comprehensive research platform reflecting the real-world treatment landscape for recurrent/metastatic head and neck tumor patients.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age ≥ 18 years
* Able to understand and willing to sign written informed consent
* Histologically or cytologically confirmed squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx or larynx)
* Patients not amenable for curative treatment who receive palliative systemic treatment or best supportive care
* Informed consent no later than four weeks after start of first-line palliative systemic treatment. For patients receiving "best supportive care only": no later than six weeks after diagnosis/recurrence or metastatic disease
Exclusion Criteria: none
Primary outcome measure(s)
Sociodemographic factors — 3 years Highest level of education, Employment status, Current professional activity, Professional risk factors, Level of self-sufficiency, Care degree
Treatments — 3 years Types of local therapies (surgery, radiotherapy, radiochemotherapy), systemic therapy and therapeutic sequences
Response rates — 3 years Response rates
Treatment decision — 3 years Physician-reported parameters affecting treatment decision
Progression-free survival — 3 years Progression-free survival
Time-to-treatment-failure — 3 years Time-to-treatment-failure
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.